Lantern Pharma (LTRN) Q3 2025 Earnings Call Summary

1Key Financial Results and Metrics

Net Loss: Approximately $4.2 million, or $0.39 per share, compared to a net loss of $4.5 million, or $0.42 per share, in Q3 2024.

R&D Expenses: $2.4 million, down from $3.7 million in the same period last year, attributed to reduced clinical trial costs and consulting expenses.

General and Administrative Expenses: Increased to $1.9 million from $1.5 million, primarily due to higher business development and investor relations costs.

Cash Position: Approximately $12.4 million as of September 30, 2025, expected to fund operations into Q3 2026.

ATM Sales: Sold 212,444 shares for about $989,000 during Q3 and an additional 144,204 shares for $634,000 post-quarter.

2Strategic Updates and Business Highlights

Clinical Milestones:

LP-184 Phase Ia trial met all primary endpoints with a 48% clinical benefit rate in evaluable patients, particularly in those with specific DNA damage repair mutations.

Progress in LP-300 and LP-284 trials, with presentations at major oncology meetings generating interest from biopharma partners.

AI Platform Development:

The RADR AI platform showcased commercial readiness with modules that can be licensed to biopharma partners.

Introduction of "withZeta," a multi-agentic AI tool aimed at improving rare cancer drug development by integrating fragmented data sources.

Regulatory Progress: Successful FDA Type C meeting for Starlight Therapeutics, providing clarity on the pediatric CNS cancer trial.

3Forward Guidance and Outlook

Upcoming Events:

KOL-led webinar on LP-184 scheduled for November 20, 2025, to discuss clinical data and development strategy.

Comprehensive data update for LP-300 expected in December.

Market Potential: Targeted indications for LP-184 represent a combined annual market potential exceeding $7 billion, with a focus on precision oncology and biomarker-driven trials.

4Bad News, Challenges, or Points of Concern

Funding Needs: The company acknowledges the need for substantial additional funding in the near future to support ongoing operations and clinical trials.

Trial Enrollment: While patient retention in trials is positive, it may delay interim analysis for LP-300, pushing expected results into early 2026.

Operational Changes: Transitioning CRO services in Asia for cost reduction may introduce operational risks, although aimed at improving efficiency.

5Notable Q&A Insights

LP-300 Trial Analysis: Interim event analysis is expected to be delayed, indicating longer patient retention, which is seen as a positive sign.

Pediatric CNS Program: An IND submission is planned soon, with initial patient dosing anticipated in early 2026.

withZeta Rollout: Early rollout is expected to be bumpy, with internal testing already underway and broader availability planned for early 2026.

Partnership Opportunities: Interest from biopharma companies in LP-184 and LP-284 for combination therapies suggests potential for strategic collaborations. Overall, Lantern Pharma is positioned for growth with significant clinical advancements and a strong AI platform, although funding and operational challenges remain key concerns.